Tyrosine kinase inhibitors (TKIs) have revolutionized CML treatment, offering more effective and better-tolerated options than previous therapies. Second- and third-generation TKIs address resistance ...
Suboptimal response or treatment failure to standard-dose imatinib are relevant problems in chronic-phase chronic myeloid leukemia patients. Insufficient adherence is one of the main causes of ...
It is important to distinguish de novo CML-BP from Ph-positive ALL before allogeneic hematopoietic cell transplantation. The effect of BCR::ABL1 mutation status on outcomes of hematopoietic cell ...
The major molecular response rate was 68% with asciminib and 49% with IS-TKIs (difference, 19% [95% CI, 10-28]; P .001). The Food and Drug Administration (FDA) has granted accelerated approval to ...
Leukemia in older adults causes symptoms like weight loss, fatigue, and night sweats. Your outlook depends on the type of leukemia you have. Leukemia is a type of cancer that affects the blood cells, ...
Scemblix outperformed standard TKIs in 96-week MMR rates, showing significant efficacy in CML treatment. FDA accelerated approval was based on 48-week data, highlighting Scemblix's early promise.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results